In a small group of 10 people with Graves' disease who did not respond to thyroid medication, 4 out of 10 became hypothyroid after 3 months of radioactive iodine treatment, but only 1 out of 10 had permanent hypothyroidism after 6 months, suggesting that a single 10 mCi dose often does not fully destroy the thyroid in this population.
Claim Context
Among 10 patients with Graves' disease who failed anti-thyroid drug therapy and received a fixed dose of 10 mCi radioactive iodine, 40% developed hypothyroidism by 3 months and only 10% achieved permanent hypothyroidism by 6 months, indicating that a single 10 mCi dose is insufficient to induce definitive hypothyroidism in most patients within this timeframe.
“At 3 months post-RAI131, 40% of subjects achieved hypothyroidism... At 6 months, 80% of subjects remained with subclinical hyperthyroidism, 10% experienced worsening hyperthyroidism and 10% had developed permanent hypothyroidism.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The pooled probability of achieving permanent hypothyroidism at 6 and 12 months after a fixed 10 mCi RAI dose in patients with Graves' disease who failed ATD, accounting for variability in thyroid volume, TRAb levels, and other prognostic factors.
A systematic review and meta-analysis of all published prospective cohort studies and randomized trials evaluating fixed-dose 10 mCi RAI in adults with Graves' disease who failed ATD, with standardized definitions of hypothyroidism (TSH >5 mIU/L and FT4 <0.7 ng/dL), stratified by baseline thyroid volume (>40 cc vs ≤40 cc), TRAb levels, and smoking status, including at least 1000 total patients across 15+ studies.
Whether a fixed 10 mCi RAI dose causes permanent hypothyroidism more frequently than a higher fixed dose (e.g., 15 mCi) or calculated dosing in patients with Graves' disease who failed ATD.
A double-blind, randomized trial of 200 adults aged 30–65 with Graves' disease and failed ATD, randomized to receive either 10 mCi or 15 mCi fixed-dose RAI, with primary outcome of permanent hypothyroidism (TSH >10 mIU/L on two occasions >3 months apart) at 12 months, controlling for baseline TRAb, thyroid volume, and smoking status.
The incidence and timing of permanent hypothyroidism following a fixed 10 mCi RAI dose in a real-world population of Graves' disease patients who failed ATD, accounting for confounding variables.
A prospective cohort study of 150 adults with Graves' disease who failed ATD, receiving fixed 10 mCi RAI, with serial TSH and FT4 measurements at 3, 6, 12, and 24 months, and collection of baseline data on thyroid volume, TRAb, smoking, and goiter size to adjust for prognostic factors.
The prevalence of hypothyroidism at a single time point (e.g., 6 months) after 10 mCi RAI in a population of Graves' disease patients, without establishing temporal sequence or causality.
A cross-sectional survey of 300 adults with Graves' disease who received 10 mCi RAI at least 6 months prior, measuring current TSH and FT4 levels and collecting retrospective data on baseline characteristics and treatment history.
Anecdotal observations of hypothyroidism development after 10 mCi RAI in individual patients, useful for generating hypotheses but not for estimating population-level outcomes.
A case series of 10–20 patients with Graves' disease treated with 10 mCi RAI, documenting individual TSH and FT4 trajectories over 12 months, including unusual responses such as transient hypothyroidism or delayed onset.